Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 2/20 | 0.31 |
| ▸ | SPR | P35270 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21796750 | 0.94 | RXRA (0.46) | RXRARXRBRXRGLRRK2CYP4F2 | |
| SCHEMBL21796835 | 0.91 | RXRA (0.45) | RXRARXRBRXRGLRRK2CYP4F2 | |
| SCHEMBL22723516 | 0.90 | RXRA (0.44) | RXRARXRBRXRGLRRK2CYP4F2 | |
| SCHEMBL20437352 | 0.88 | LRRK2 (0.40) | RXRARXRBRXRGLRRK2LMNA | |
| SCHEMBL28610255 | 0.88 | LRRK2 (0.40) | RXRARXRBRXRGLRRK2LMNA | |
| SCHEMBL18398983 | 0.88 | LRRK2 (0.40) | RXRARXRBRXRGLRRK2LMNA | |
| SCHEMBL21796642 | 0.86 | RXRA (0.48) | RXRARXRBRXRGLRRK2CYP4F2 | |
| SCHEMBL28604377 | 0.84 | RXRA (0.46) | RXRARXRBRXRGLRRK2CYP4F2 | |
| SCHEMBL21796571 | 0.84 | RXRA (0.46) | RXRARXRBRXRGLRRK2CYP4F2 | |
| SCHEMBL21796635 | 0.83 | RXRA (0.45) | RXRARXRBRXRGLRRK2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137510-B | Compound (I) | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-07-20 | — | — | CN | disclosed |
| US-11034696-B2 | Compounds for inhibiting LRRK2 kinase activity | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
| US-20210130339-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-06 | — | — | US | disclosed |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3325449-B1 | HETEROCYCLIC COMPOUNDS, PARTICULARLY PYRIMIDINYLINDAZOLE COMPOUNDS FOR TREATING PARKINSON'S DISEASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-01-13 | — | — | EP | disclosed |
| US-10858367-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20200079777-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858367-B2 | Compounds | LRRK2, PARK7, PINK1 | RXRA 4584/4885RXRB 4530/4885RXRG 4371/4885 |
| US-20210130339-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | RXRA 4584/4885RXRB 4530/4885RXRG 4371/4885 |
| US-11034696-B2 | Compounds for inhibiting LRRK2 kinase activity | LRRK2, BRSK2, MAPKAPK2 | RXRA 4707/4885RXRB 4550/4885RXRG 4468/4885 |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | LRRK2, PARK7, PINK1 | RXRA 4652/4885RXRB 4413/4885RXRG 4409/4885 |
| US-20200079777-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | RXRA 4559/4885RXRB 4482/4885RXRG 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.